HR 3029: Nucleic Acid Standards for Biosecurity Act

HR 3029 in plain English: This bill requires the National Institute of Standards and Technology (NIST) to develop best practices and technical standards for nucleic acid synthesis — the process of creating custom DNA and RNA — to reduce biosecurity risks such as the accidental or intentional creation of dangerous biological agents. NIST must convene stakeholders, report findings to Congress, and address risks related to artificial intelligence in this field. The bill authorizes $5,000,000 per year for fiscal years 2026 through 2030 for these activities.

Stated purpose

The bill directs the National Institute of Standards and Technology (NIST) to develop best practices and technical standards for screening nucleic acid synthesis, in order to reduce biosecurity risks such as the accidental or intentional creation of dangerous biological agents.

Key points

• Requires NIST to develop biosecurity best practices and technical standards for nucleic acid (DNA/RNA) synthesis
• Authorizes $5,000,000 per year from 2026 through 2030 to support this work
• NIST must convene stakeholders to establish and update consensus priorities for synthetic nucleic acid screening
• NIST must submit a summary of stakeholder findings to Congress within a specified period
• Requires NIST to address biosecurity risks from artificial intelligence use in engineering biology and biomanufacturing

Arguments supporters make

• Giving NIST a clear legal mandate ensures the federal government keeps pace with fast-moving biotechnology and closes potential gaps that bad actors could exploit to create dangerous pathogens.
• Bringing together industry, universities, and nonprofits through a formal consortium produces practical, widely accepted standards rather than rules written without input from those doing the work.
• Addressing AI-related risks in bioengineering now, before problems emerge, is more cost-effective and safer than reacting after a biosecurity incident occurs.

Arguments opponents make

• Authorizing $5 million per year for a new NIST program adds government spending and bureaucracy, and critics may question whether voluntary best practices will be adopted widely enough to meaningfully improve security.
• New screening standards could slow down or raise costs for legitimate medical and agricultural research, potentially putting U.S. scientists at a disadvantage compared to researchers in countries without similar requirements.
• A 2023 executive order already directed NIST to work on nearly identical standards, so some argue this bill duplicates existing efforts rather than filling a true gap.

Tradeoffs

Tighter biosecurity screening standards may reduce the risk of misuse of synthetic biology tools, but could also create compliance burdens or delays for researchers and companies doing beneficial work; the bill tries to balance both by relying on voluntary consensus standards developed with industry input rather than binding regulation.

Current status in Congress: Passed House.

NewsClear — neutral news & congressional tracking · Bill of the Week